Use of a Polyurethane Foam as a Wound Dressing in Negative Pressure Therapy
AssigneePaul Hartmann AG
InventorsAxel ECKSTEIN, Pierre CROIZAT, Ulrich FINK, Krzysztof-Daniel MALOWANIEC
Life of this patent
Estimating the term…
Abstract
A device for negative pressure wound therapy having a cover material for air-tight sealing of the wound space connected to a negative pressure source; and a wound dressing having an open-cell polyurethane foam. The open-cell polyurethane foam has special properties, in particular a tensile strength after three days of storage in bovine serum, measured in accordance with DIN 53571, between 80 kPa and 300 kPa. The open-cell polyurethane foam may be used as a wound dressing in negative pressure wound therapy.
Claims18
A device for negative pressure wound therapy comprising
- (a) a cover material for air-tight sealing of the wound space;
- (b) optionally, a connector of a negative pressure source;
- and
- (c) an open-cell polyurethane foam as a wound dressing, obtained by reaction of a mixture comprising the components
- (i) polyisocyanate selected from the group consisting of diphenylmethane diisocyanate (MDI), mixtures of monomeric diphenylmethane diisocyanates and higher-nucleus homologues of diphenylmethane diisocyanate (polymeric MDI), tetramethylene diisocyanate (TMDI), hexamethylene diisocyanate (HDI), toluylene diisocyanate (TDI) and mixtures thereof,
- (ii) polyol,
- (iii) blowing agent, and
- (iv) catalyst,
- wherein the open-cell polyurethane foam has an air permeability of 1,000 to 8,000 l/(m2sec), measured in accordance with DIN EN ISO 9237.
(canceled)
Use of an open-cell polyurethane foam as a wound dressing for negative pressure wound therapy, whereby the open-cell polyurethane foam is obtainable by reaction of a mixture comprising the components
- (i) polyisocyanate selected from diphenylmethane diisocyanate (MDI), in particular, 4,4′-diphenylmethane diisocyanate (4,4′-MDI), mixtures of monomeric diphenylmethane diisocyanates and higher-nucleus homologues of diphenylmethane diisocyanate (polymeric MDI), tetramethylene diisocyanate (TMDI), hexamethylene diisocyanate (HDI), toluylene diisocyanate (TDI) or mixtures thereof can be used to produce the polyurethanes,
- (ii) polyol, in particular polyester polyol,
- (iii) blowing agent, and
- (iv) catalyst,
- and
- wherein the open-cell polyurethane foam has an air permeability of 1,000 to 8,000 l/(m2sec), measured in accordance with DIN EN ISO 9237.
A method for negative pressure wound therapy, said method comprising dressing a wound with an open-cell polyurethane foam obtained by reaction of a mixture comprising the components
- (i) polyisocyanate selected from the group consisting of diphenylmethane diisocyanate (MDI), mixtures of monomeric diphenylmethane diisocyanates and higher-nucleus homologues of diphenylmethane diisocyanate (polymeric MDI), tetramethylene diisocyanate (TMDI), hexamethylene diisocyanate (HDI), toluylene diisocyanate (TDI) and mixtures thereof, which is used to produce the polyurethane,
- (ii) polyester polyol,
- (iii) blowing agent, and
- (iv) catalyst,
- wherein the open-cell polyurethane foam has an air permeability of 1,000 to 8,000 l/(m2sec), measured in accordance with DIN EN ISO 9237.
Dependencies are inferred from the claim text.